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Major advances in the disciplines of hematology, genetics,
biochemistry, and chemistry over the past decades have
empowered investigators with the background and methods
required for development of customized molecular-targeted
therapies. The ability to identify signaling pathways that are
dysregulated, to determine the associated mutations, and to
develop chemical drugs toward a desired correction is now a
realistic work ﬂow. The landmark demonstration that BCR-
ABL could be molecularly targeted and could have a major
impact upon disease progression really ignited the ﬁeld of
targeted therapies for hematologic malignancies. Through
much hard work, we now know the key drivers of some
hematologic malignancies, and depending on the particular
disease, we have an arsenal of agents available to act at
multiple nodal points. Some enabling technologies that have
been a key for these advances include small molecule screen-
ing, high throughput whole genome sequencing, mouse
models for cancer, and gene and microRNA expression
array analyses. In this special issue, we present a collection
of seven articles that contribute to our understanding of
molecular targets and the development of approaches for
their inhibition or rationale use of existing agents or their
derivatives. These targets range from very early initiators
of malignancy to molecules that are already advanced into
clinical studies.
The ﬁrst paper in this issue by A. Fathi and T. Abdel-
Wahab “Mutations in epigenetic modiﬁers in myeloid malig-
nancies and the prospect of novel epigenetic-targeted therapy”
addresses the series of mutations identiﬁed that alter DNA
and/or histone lysine methylation. These early epigenetic
changes predispose to leukemogenesis and are relevant
in acute myeloid leukemia (AML) and myelodysplastic
syndrome (MDS) patients. The second paper by J. Okabe-
Kado et al. “Extracellular NM23 protein as a therapeutic
target for hematologic malignancies” describes extracellular
NM23-H1 protein and its relationship with altered signaling
pathways and growth/survival in AML. The third paper by S.
Verma et al. “Gab adapter proteins as therapeutic targets for
hematologic disease” describes the Grb2-associated adapter
proteins (Gabs) as potential therapeutic targets playing
major roles in regulation of multiple signaling pathways.
These ﬁrst three papers describe potential new targets that
require further validation and greater speciﬁcity, but could
have signiﬁcant impact on the initiation and progression of
hematologic malignancy.
The fourth paper by X. Liu et al. “Molecular targets for
the treatment of juvenile myelomonocytic leukemia” describes
the outstanding progress made in identifying the mutations
associated with activation of the Ras pathway in juvenile
myelomonocytic leukemia (JMML), several of which are
already targets of drugs that are being tested such as
Ras and SHP-2. This paper additionally points toward
protein:protein interactions as potential therapeutic targets
such as SHP-2/Gab2 in hematopoiesis. The ﬁfth paper by
P. Argyriou et al. “The role of mTOR inhibitors for the
treatment of B-cell lymphomas” focuses on the downstream
activation of the mTOR pathway and the development and
testingofnewrapaloguesandATP-competitiveinhibitorsfor
clinical use. The mTOR pathway is central to cell survival
and metabolism and represents a common target for many
types of cancers. The sixth paper by F. Tziﬁ et al. “The role
of Bcl2 family of apoptosis regulator proteins in acute and2 Advances in Hematology
chronic leukemias” describes the exciting new advances in
understanding and targeting the Bcl-2 family of proteins
and gives a comprehensive update on new agents that are
in clinical studies targeting survival in acute and chronic
leukemias. All of these three papers describe bona ﬁde
targets that are already subject to signiﬁcant validation and
commercial drug development.
The seventh paper by P. Koehler et al. “Engineered T cells
for the adoptive therapy of B cell-chronic lymphocytic leukemia
(B-CLL)” in the issue addresses immunotherapy using T-
cell therapies against CD19, which has recently been very
successful and received widespread attention for treatment
of chronic lymphocytic leukemia. This approach promises
to provide sustained targeted therapy based on cell surface
phenotype and although it has to deal with issues such as
B-cell deﬁciency and intravenous immunoglobuin infusions,
such approaches when combined with chemotherapy are
very promising as a form of targeted gene-based therapy.
In summary, the articles in this special issue address the
spectrum of new targeted therapy development, from basic
understandings of structure-function to mature rationale
drugs already being tested in patients. We sought to cover
thefullspectrumoftherapeuticdevelopmentandarepleased
to present a series of papers that do just that. As editors
of this issue, we appreciate the important contributions
of the authors of these review articles and hope that this
issue will encourage expanded translational research toward
developing novel therapies for hematologic malignancies.
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